Reprogramming leukemia cells to terminal differentiation and growth arrest by RNA interference of PU.1

Michael Papetti, Arthur I. Skoultchi

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Malignant transformation often leads to both loss of normal proliferation control and inhibition of cell differentiation. Some tumor cells can be stimulated to reenter their differentiation program and to undergo terminal growth arrest. The in vitro differentiation of mouse erythroleukemia (MEL) cells is an important example of tumor cell reprogramming. MEL cells are malignant erythroblasts that are blocked from differentiating into mature RBC due to dysregulated expression of the transcription factor PU.1, which binds to and represses GATA-1, the major transcriptional regulator of erythropoiesis. We used RNA interference to ask whether inhibiting PU.1 synthesis was sufficient to cause MEL cells to lose their malignant properties. We report here that transfection of MEL cells with a PU.1-specific short interfering RNA oligonucleotide causes the cells to resume erythroid differentiation, accumulate hemoglobin, and undergo terminal growth arrest. RNA interference directed at specific, aberrantly expressed transcription factors may hold promise for the development of potent antitumor therapies in other hematologic malignancies.

Original languageEnglish (US)
Pages (from-to)1053-1062
Number of pages10
JournalMolecular Cancer Research
Volume5
Issue number10
DOIs
StatePublished - Oct 1 2007

Fingerprint

RNA Interference
Leukemia, Erythroblastic, Acute
Leukemia
Growth
Transcription Factors
Erythroblasts
Erythropoiesis
Hematologic Neoplasms
Oligonucleotides
Small Interfering RNA
Transfection
Cellular Reprogramming
Cell Differentiation
Neoplasms
Hemoglobins

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research

Cite this

Reprogramming leukemia cells to terminal differentiation and growth arrest by RNA interference of PU.1. / Papetti, Michael; Skoultchi, Arthur I.

In: Molecular Cancer Research, Vol. 5, No. 10, 01.10.2007, p. 1053-1062.

Research output: Contribution to journalArticle

@article{b425357e7767485590bc7b04344d2878,
title = "Reprogramming leukemia cells to terminal differentiation and growth arrest by RNA interference of PU.1",
abstract = "Malignant transformation often leads to both loss of normal proliferation control and inhibition of cell differentiation. Some tumor cells can be stimulated to reenter their differentiation program and to undergo terminal growth arrest. The in vitro differentiation of mouse erythroleukemia (MEL) cells is an important example of tumor cell reprogramming. MEL cells are malignant erythroblasts that are blocked from differentiating into mature RBC due to dysregulated expression of the transcription factor PU.1, which binds to and represses GATA-1, the major transcriptional regulator of erythropoiesis. We used RNA interference to ask whether inhibiting PU.1 synthesis was sufficient to cause MEL cells to lose their malignant properties. We report here that transfection of MEL cells with a PU.1-specific short interfering RNA oligonucleotide causes the cells to resume erythroid differentiation, accumulate hemoglobin, and undergo terminal growth arrest. RNA interference directed at specific, aberrantly expressed transcription factors may hold promise for the development of potent antitumor therapies in other hematologic malignancies.",
author = "Michael Papetti and Skoultchi, {Arthur I.}",
year = "2007",
month = "10",
day = "1",
doi = "10.1158/1541-7786.MCR-07-0145",
language = "English (US)",
volume = "5",
pages = "1053--1062",
journal = "Molecular Cancer Research",
issn = "1541-7786",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - Reprogramming leukemia cells to terminal differentiation and growth arrest by RNA interference of PU.1

AU - Papetti, Michael

AU - Skoultchi, Arthur I.

PY - 2007/10/1

Y1 - 2007/10/1

N2 - Malignant transformation often leads to both loss of normal proliferation control and inhibition of cell differentiation. Some tumor cells can be stimulated to reenter their differentiation program and to undergo terminal growth arrest. The in vitro differentiation of mouse erythroleukemia (MEL) cells is an important example of tumor cell reprogramming. MEL cells are malignant erythroblasts that are blocked from differentiating into mature RBC due to dysregulated expression of the transcription factor PU.1, which binds to and represses GATA-1, the major transcriptional regulator of erythropoiesis. We used RNA interference to ask whether inhibiting PU.1 synthesis was sufficient to cause MEL cells to lose their malignant properties. We report here that transfection of MEL cells with a PU.1-specific short interfering RNA oligonucleotide causes the cells to resume erythroid differentiation, accumulate hemoglobin, and undergo terminal growth arrest. RNA interference directed at specific, aberrantly expressed transcription factors may hold promise for the development of potent antitumor therapies in other hematologic malignancies.

AB - Malignant transformation often leads to both loss of normal proliferation control and inhibition of cell differentiation. Some tumor cells can be stimulated to reenter their differentiation program and to undergo terminal growth arrest. The in vitro differentiation of mouse erythroleukemia (MEL) cells is an important example of tumor cell reprogramming. MEL cells are malignant erythroblasts that are blocked from differentiating into mature RBC due to dysregulated expression of the transcription factor PU.1, which binds to and represses GATA-1, the major transcriptional regulator of erythropoiesis. We used RNA interference to ask whether inhibiting PU.1 synthesis was sufficient to cause MEL cells to lose their malignant properties. We report here that transfection of MEL cells with a PU.1-specific short interfering RNA oligonucleotide causes the cells to resume erythroid differentiation, accumulate hemoglobin, and undergo terminal growth arrest. RNA interference directed at specific, aberrantly expressed transcription factors may hold promise for the development of potent antitumor therapies in other hematologic malignancies.

UR - http://www.scopus.com/inward/record.url?scp=35948933434&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35948933434&partnerID=8YFLogxK

U2 - 10.1158/1541-7786.MCR-07-0145

DO - 10.1158/1541-7786.MCR-07-0145

M3 - Article

VL - 5

SP - 1053

EP - 1062

JO - Molecular Cancer Research

JF - Molecular Cancer Research

SN - 1541-7786

IS - 10

ER -